Abstract:You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) III1 Apr 2018PD57-08 TUMORAL CD8+ T CELLS CORRELATE WITH FAVORABLE OUTCOME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS Jiajun Wang, Li Liu, Wei Xi, Jiejie Xu, and Jianming Guo Jiajun WangJiajun Wang More articles by this author , Li LiuLi Liu More articles by this author , Wei XiWei Xi More articles by this author , Jiejie XuJiejie Xu More articles by this author , and Jianming GuoJianming Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2652AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES CD8+ T cells play a central role in cancer immune elimination, and tyrosine kinase inhibitor (TKI) therapy could enhance their anti-tumor function. We aim to investigate the predictive value of CD8+ T cells for TKI therapy in metastatic renal cell carcinoma (mRCC) patients. METHODS One hundred and thirty-eight metastatic mRCC patients treated with TKIs were retrospectively scanned, and 111 eligible patients were finally enrolled. CD8+ T cell density and major histocompatibility complex (MHC) class I expression in tumor tissues was assessed by immunohistochemistry. Associations between CD8+ T cell density, MHC class I expression and local immune cytolytic activity were also assessed in the TCGA cohort. RESULTS CD8+ T cells were observed in mRCC samples (median density 45 cells/mm2, range 0-2750 cells/mm2). Patients with high density of CD8+ T cells showed higher response rate (P=0.002), longer overall survival (OS) (hazard ratio=0.510, P=0.005) and longer progression-free survival (PFS) (hazard ratio=0.591, P=0.012) under TKI therapy. Multivariate Cox analyses identified high CD8+ T cell density as an independent prognostic factor for both OS (hazard ratio=0.559, P=0.027) and PFS (hazard ratio=0.574, P=0.017). We also identified close relationship between high CD8+ T cell infiltration, activated antigen presentation mechanism and enhanced immune cytolytic activity. Moreover, mRCC patients with both high tumoral CD8+ T cell density and high MHC class I expression showed significantly prolonged survival (P<10-4). CONCLUSIONS Tumoral CD8+ T cell density could serve as a predictive marker for TKI therapy in mRCC patients, especially in those with high MHC class I expression. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1069-e1070 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jiajun Wang More articles by this author Li Liu More articles by this author Wei Xi More articles by this author Jiejie Xu More articles by this author Jianming Guo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression

The Prognostic Significance of CDK6 Expression in Renal Cell Carcinoma Treated by Immune Checkpoint Plus Tyrosine Kinase Inhibition.

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Unfavorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Metastatic Renal Cell Carcinoma after Radical Nephrectomy with Increased ADAM9 Expression

Effects of PYCR1 on Prognosis and Immunotherapy Plus Tyrosine Kinase Inhibition Responsiveness in Metastatic Renal Cell Carcinoma Patients

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKls) monotherapy or TKI-IO combination therapy.

FHL2 Determines Poor Outcomes and Responsiveness of Immunotherapy Plus Tyrosine Kinase Inhibition in Metastatic Renal Cell Carcinoma

MP18-03 TUMOR-INFILTRATING CD39+CD8+ T CELLS DETERMINE POOR PROGNOSIS AND IMMUNE EVASION IN CLEAR-CELL RENAL CELL CARCINOMA PATIENTS

Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma

Tumor Infiltrating CD19+ B Lymphocytes Predict Prognostic and Therapeutic Benefits in Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

CXCR1 Expression Predicts Benefit from Tyrosine Kinase Inhibitors Therapy in Patients with Metastatic Renal Cell Carcinoma

Checkpoint Molecule PD-1-assisted CD8+ T Lymphocyte Count in Tumor Microenvironment Predicts Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

Single-Cell Analysis Identifies Distinct Populations of Cytotoxic CD4+ T Cells Linked to the Therapeutic Efficacy of Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

Tumor-infiltrating CD39+CD8+ T Cells Determine Poor Prognosis and Immune Evasion in Clear Cell Renal Cell Carcinoma Patients

Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment

HMOX1 Pathway Signature Predicts Clinical Benefit from Immunotherapy Plus Tyrosine Kinase Inhibitor Therapy in Advanced Renal Cell Carcinoma.

Clinical effectiveness of second-line TKI plus PD-1 following targeted therapy in patients with metastatic non-clear cell renal cell carcinoma: A real-world study.

The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

PD57-08 TUMORAL CD8+ T CELLS CORRELATE WITH FAVORABLE OUTCOME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS